Courier-Post on MSN

Prison term for Marcello DiPietro III, former Evesham restaurant owner

A former Evesham restaurateur has received a three-year prison term for fraudulently obtaining pandemic relief funds. Marcello DiPietro III also must pay restitution of $2.7 million under a sentence ...
Jagonews24

HC delivers split verdict on legality of NCT operation deal

The two-judge bench delivered the split verdict on Thursday (4 December), expressing differing opinions. As per procedure, ...
TMCnet

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease in Japan

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Passport Information

Passport Apply Online - Check How Can I Apply Through passportindia.gov.in for a Passport and the required documents, How to book Passport Appointment Online, Know about How to Apply for Indian ...
TMCnet

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...
Pharmabiz

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

ASUR Calls for a Shareholders' Meeting

Grupo Aeroportuario del Sureste, S.A.B. de C.V.(NYSE: ASR; BMV: ASUR) (ASUR), a leading international airport group with operations in Mexico, the United States, and Colombia, today announced the call ...

New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's ...
Federal News Network

The shutdown may be over, but its ripple effects on lending and tax compliance are just beginning

"We have more...pain to work through before we get to a place of stability, where credit markets operate in some kind of normal fashion," Dave Bohrman said.
Eastern Mirror

TR Zeliang inaugurates centre for oil palm farmers in Peren

DIMAPUR — Deputy Chief Minister TR Zeliang on Thursday inaugurated the Godrej Agrovet Ltd. ‘Samadhan’ One-Stop Solution ...
SeeNews

Bulgaria's National Decarbonisation Fund: Scaling up two decades of sustainable finance success

Luba Nikiforova, Executive Director of the Energy Efficiency and Renewable Sources Fund (EERSF), explains how the Fund is ...
Le Lézard

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIKtm (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA ...